Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 28 April 2018)

Research article
Evaluating clinical effectiveness of 13-valent pneumococcal conjugate vaccination against pneumonia among middle-aged and older adults in Catalonia: results from the EPIVAC cohort study
Benefits using the 13-valent pneumococcal conjugate vaccine (PCV13) in adults are controversial. This study investigated clinical effectiveness of PCV13 vaccination in preventing hospitalisation from pneumonia…
Authors: Angel Vila-Corcoles, Olga Ochoa-Gondar, Cinta de Diego, Eva Satue, María Aragón, Angel Vila-Rovira, Frederic Gomez-Bertomeu, Ramon Magarolas, Enric Figuerola-Massana, Xavier Raga, Mar O. Perez and Frederic Ballester
Citation: BMC Infectious Diseases 2018 18:196
Published on: 27 April 2018